Growing Demand Theranica markets Nerivio for migraine treatment with FDA clearance and CE mark, targeting a large patient base including adolescents. Sales opportunities exist in hospitals, clinics, and pediatric neurology practices seeking non-drug, neuromodulation options with proven safety and scalable adoption.

Pediatric Focus Significant emphasis on pediatric and adolescent migraine care presents a channel for pediatric specialists, schools' health programs, and family medicine to integrate non-pharmacologic interventions, offering a differentiator for providers serving younger patients.

Clinical Adoption With over 650,000 migraine treatments delivered and ongoing presence at medical conferences, there is momentum for expanding reimbursement conversations, formulary placements, and training services to expedite clinician onboarding and patient access.

Strategic Partnerships Potential collaborations with pain management clinics, neurology networks, and telemedicine platforms can extend Nerivio’s reach, leveraging remote patient monitoring and data-driven outcomes to support adoption and payer acceptance.

Financial Reach Revenue scale and substantial funding indicate capacity for expansion into adjacent neuromodulation indications or new geographic markets, presenting upsell opportunities for clinics already using Nerivio and for distributors in regions with rising migraine prevalence.